Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer.

MLA

Conibear, John, et al. “Study Protocol for the SARON Trial: A Multicentre, Randomised Controlled Phase III Trial Comparing the Addition of Stereotactic Ablative Radiotherapy and Radical Radiotherapy with Standard Chemotherapy Alone for Oligometastatic Non-Small Cell Lung Cancer.” BMJ Open, vol. 8, no. 4, Apr. 2018, p. e020690. EBSCOhost, https://doi.org/10.1136/bmjopen-2017-020690.

APA

Conibear, J., Chia, B., Ngai, Y., Bates, A. T., Counsell, N., Patel, R., Eaton, D., Faivre-Finn, C., Fenwick, J., Forster, M., Hanna, G. G., Harden, S., Mayles, P., Moinuddin, S., & Landau, D. (2018). Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer. BMJ Open, 8(4), e020690. https://doi.org/10.1136/bmjopen-2017-020690

Chicago

Conibear, John, Brendan Chia, Yenting Ngai, Andrew Tom Bates, Nicholas Counsell, Rushil Patel, David Eaton, et al. 2018. “Study Protocol for the SARON Trial: A Multicentre, Randomised Controlled Phase III Trial Comparing the Addition of Stereotactic Ablative Radiotherapy and Radical Radiotherapy with Standard Chemotherapy Alone for Oligometastatic Non-Small Cell Lung Cancer.” BMJ Open 8 (4): e020690. doi:10.1136/bmjopen-2017-020690.